Posted by Michael Wonder on 26 Jul 2023
Jardiance (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
25 July 2023 - Jardiance (empagliflozin) is the first SGLT-2 inhibitor to demonstrate a statistically significant reduction in all cause hospitalisations in people with chronic kidney disease versus placebo.
The European Commission approved Jardiance (empagliflozin) for the treatment of adults with chronic kidney disease, Boehringer Ingelheim and Eli Lilly announced today.
